PALVELLA THERAPEUTICS, INC. (PVLA) Stock Research
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Latest price: 122.58 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| JENKINS GEORGE M | sell | 2026-10-13 | 136092.15 |
| JENKINS GEORGE M | sell | 2026-10-13 | 257555.28 |
| JENKINS GEORGE M | sell | 2026-10-13 | 129175.4 |
| JENKINS GEORGE M | sell | 2026-10-12 | 327524.32 |
| JENKINS GEORGE M | sell | 2026-10-12 | 196063.87 |
| JENKINS GEORGE M | sell | 2026-10-12 | 111475.07 |
| JENKINS GEORGE M | sell | 2026-10-12 | 447585.68 |
| JENKINS GEORGE M | sell | 2026-10-13 | 212454.94 |
| JENKINS GEORGE M | sell | 2026-10-12 | 675681.07 |
| JENKINS GEORGE M | sell | 2026-10-13 | 76662.26 |